

Production of 5-aminovalerate and glutarate using metabolically engineered *Escherichia coli*

김동인, 박시재, 김은영<sup>1</sup>, 노 원<sup>1</sup>, 박혜민, 오영훈<sup>1</sup>, 이승환<sup>1</sup>, 송봉근<sup>1</sup>, 제갈종건<sup>1</sup>, 이상엽\*

카이스트; <sup>1</sup>KRICT

(leesy@kaist.ac.kr\*)

*Escherichia coli* was metabolically engineered for the production of 5-aminovalerate (5AVA) and glutarate. When the recombinant *E. coli* WL3110 strain harboring the *Pseudomonas putida* *davAB* genes encoding delta-aminovaleramidase and lysine 2-monooxygenase was cultured, 3.6 g/L of 5AVA was produced. When the *davAB* genes were introduced into recombinant *E. coli* strain XQ56 allowing improved l-lysine synthesis, 0.27 and 0.5 g/L of 5AVA were produced. We further converted 5AVA to glutarate by expression of the *P. putida* *gabTD* genes encoding 5AVA aminotransferase and glutarate semialdehyde dehydrogenase. When recombinant *E. coli* WL3110 strain expressing the *davAB* and *gabTD* genes was cultured, 1.7 g/L of glutarate was produced. [This work was supported by the Technology Development Program to Solve Climate Changes on Systems Metabolic Engineering for Biorefineries from the Ministry of Education, Science, and Technology (MEST) through the National Research Foundation of Korea(NRF-2012-C1AAA001-2012M1A2A2026556). Further support by the World Class University program (R32-2008-000-10142-0) of the MEST are appreciated]